IMFINZI® (durvalumab)-based regimen reduced the risk of death by 22% in early gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.
University of California

Gene therapy delivers lasting immune protection in children with rare disorder

Long-term follow-up shows 95% success rate, no serious complications in largest ADA-SCID gene therapy study to date ...
Frontiers

Innate immune defences in respiratory virus-host interactions and their implications for therapy

Background:Respiratory viruses, including influenza viruses, respiratory syncytial virus (RSV), coronaviruses, and other emerging zoonotic pathogens, remain ...

Human cells activate self-destruction when viruses disrupt RNA production, study shows

They disable our defenses and hijack the cellular machinery in order to multiply successfully. For example, the herpes simplex virus 1, which causes blister-like skin rashes, and influenza viruses ...
Science Daily

Exercise might be the key to a younger, sharper immune system

Endurance exercise may train the immune system as much as the muscles. Older adults with decades of running or cycling had ...

Pilatus Biosciences Announces Issuance of Foundational Global Patent Covering Novel CD36-Targeted Immunotherapy

Pilatus Biosciences Announces Issuance of Foundational Global Patent Covering Novel CD36-Targeted Immunotherapy ...

How pollution and the microbiome interact with Tregs, the immune system regulators whose discovery won the Nobel Prize

A special group of immune cells known as regulatory T cells, or Tregs for short, became an overnight sensation when a trio of ...

Genethon: Data from GNT-018-IDES Trial Supports Feasibility of imlifidase as Pretreatment in Gene Therapy Treatment for Patients With Crigler-Najjar Syndrome Who Are Immune to AAV

Genethon, a worldwide pioneer and leader in research and development of gene therapy for rare genetic diseases, and Hansa Biopharma, a Sweden-based leader in ...
The Malaysian Reserve

Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

FLASH 2 Study Interim Efficacy Analysis Targeted for 1H2026 Enrollment Update Remains on Track for 4Q2025 PRINCETON, N.J., Oct. 7, 2025 /PRNewswire/ -- ...